SK Biopharmaceuticals emerges from pandemic delays with pitch for $822M IPO

On Monday, SK Biopharmaceuticals revealed that it’s eyeing $822 million in what would be the country’s biggest public debut in three years.

Plans for the IPO began as early as last October, when SK filed a preliminary application to the Korean Exchange. Expectations were high, with analysts predicting that it could fetch upwards of 1 trillion won (close to $850 million).